These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8051620)

  • 1. Immunological and virological interactions in patients receiving passive immunotherapy with HIV-1 neutralizing monoclonal antibodies.
    Hinkula J; Bratt G; Gilljam G; Nordlund S; Broliden PA; Holmberg V; Olausson-Hansson E; Albert J; Sandström E; Wahren B
    J Acquir Immune Defic Syndr (1988); 1994 Sep; 7(9):940-51. PubMed ID: 8051620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
    Montefiori DC; Graham BS; Zhou J; Zhou J; Bucco RA; Schwartz DH; Cavacini LA; Posner MR
    J Clin Invest; 1993 Aug; 92(2):840-7. PubMed ID: 8349820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
    Carrow EW; Vujcic LK; Glass WL; Seamon KB; Rastogi SC; Hendry RM; Boulos R; Nzila N; Quinnan GV
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV type 1 envelope glycoprotein 120 carboxy-terminal peptide-induced human T cell lines selectively suppress heterogeneous proliferative T cell responses to soluble antigens.
    Wilson SE; Habeshaw JA; Addawe MA; Hounsell EF; Oxford JS
    AIDS Res Hum Retroviruses; 1997 Oct; 13(15):1313-24. PubMed ID: 9339848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human immunodeficiency virus (HIV) type 1 strain MN neutralizing antibody in HIV-infected children: correlation with clinical status and prognostic value.
    Robert-Guroff M; Roilides E; Muldoon R; Venzon D; Husson R; Marshall D; Gallo RC; Pizzo PA
    J Infect Dis; 1993 Mar; 167(3):538-46. PubMed ID: 7680059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two PBMC-based neutralization assays depict low reactivity of both anti-V3 monoclonal antibodies and immune sera against HIV-1 primary isolates.
    Candotti D; Rosenheim M; Huraux JM; Agut H
    J Virol Methods; 1997 Feb; 64(1):81-93. PubMed ID: 9029533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4-imitating human antibodies in HIV infection and anti-idiotypic vaccination.
    Deckert PM; Ballmaier M; Lang S; Deicher H; Schedel I
    J Immunol; 1996 Jan; 156(2):826-33. PubMed ID: 8543839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody.
    Emini EA; Schleif WA; Nunberg JH; Conley AJ; Eda Y; Tokiyoshi S; Putney SD; Matsushita S; Cobb KE; Jett CM
    Nature; 1992 Feb; 355(6362):728-30. PubMed ID: 1741059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIV type 1 glycoprotein 120.
    Cavacini LA; Samore MH; Gambertoglio J; Jackson B; Duval M; Wisnewski A; Hammer S; Koziel C; Trapnell C; Posner MR
    AIDS Res Hum Retroviruses; 1998 May; 14(7):545-50. PubMed ID: 9591708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Passive immunization with a human immunodeficiency virus type 1-neutralizing monoclonal antibody in Hu-PBL-SCID mice: isolation of a neutralization escape variant.
    Andrus L; Prince AM; Bernal I; McCormack P; Lee DH; Gorny MK; Zolla-Pazner S
    J Infect Dis; 1998 Apr; 177(4):889-97. PubMed ID: 9534960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding of HIV-1 virions or gp120-anti-gp120 immune complexes to HIV-1-infected quiescent peripheral blood mononuclear cells reveals latent infection.
    Briant L; Coudronnière N; Robert-Hebmann V; Benkirane M; Devaux C
    J Immunol; 1996 May; 156(10):3994-4004. PubMed ID: 8621941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular immune responses in asymptomatic human immunodeficiency virus type 1 (HIV-1) infection and effects of vaccination with recombinant envelope glycoprotein of HIV-1.
    Gorse GJ; Simionescu RE; Patel GB
    Clin Vaccine Immunol; 2006 Jan; 13(1):26-32. PubMed ID: 16425996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two new human monoclonal antibodies against HIV type 1 glycoprotein 120: characterization and neutralizing activities against HIV type 1 strains.
    Février M; Boudet F; Deslandres A; Theze J
    AIDS Res Hum Retroviruses; 1995 Apr; 11(4):491-500. PubMed ID: 7543271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of viral load and immune complex load on CD4+ lymphocytes as a consequence of highly active antiretroviral treatment (HAART) in HIV-infected hemophilia patients.
    Daniel V; Süsal C; Melk A; Weimer R; Kröpelin M; Zimmermann R; Huth-Kühne A; Uhle C; Opelz G
    Immunol Lett; 1999 Aug; 69(2):283-9. PubMed ID: 10482364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I/IIA clinical study with a chimeric mouse-human monoclonal antibody to the V3 loop of human immunodeficiency virus type 1 gp120.
    Günthard HF; Gowland PL; Schüpbach J; Fung MS; Böni J; Liou RS; Chang NT; Grob P; Graepel P; Braun DG
    J Infect Dis; 1994 Dec; 170(6):1384-93. PubMed ID: 7995976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of anti-CD4 idiotype vaccination in HIV positive volunteers.
    Schedel I; Sutor GC; Hunsmann G; Jurkiewicz E
    Vaccine; 1999 Apr; 17(15-16):1837-45. PubMed ID: 10217581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
    Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
    J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels.
    Hogervorst E; Jurriaans S; de Wolf F; van Wijk A; Wiersma A; Valk M; Roos M; van Gemen B; Coutinho R; Miedema F
    J Infect Dis; 1995 Apr; 171(4):811-21. PubMed ID: 7706807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
    Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX
    AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.